

Investor Webinar

Melbourne, Australia; 22 June 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, reminds shareholders that an investor webinar will be held today, Monday 22 June 2026, at 8:30am AEST, hosted by CEO and Managing Director, Dr Kilian Kelly, and Chair, Dr Geoff Brooke. Please visit the following link to register: <https://cynata.com/webinars/rvJo2r-cynata-investor-webinar>

A copy of the presentation to be delivered during the webinar is attached to this announcement.

After the webinar is complete, a recording will be available on the Company’s [InvestorHub](#) portal.

-ENDS-

Authorised for release by Dr Kilian Kelly, CEO & Managing Director

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Group](#).

ersonal use only



Investor Webinar: Results Update

June 2026

(ASX:CYP)

Important Information

Summary information

This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (**CYP**, or **Cynata**) which is current as at 19 June 2026. This Presentation should be read in conjunction with CYP's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (**ASX**), which are available at www.asx.com.au.

Not an offer

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities.

Investment risk and past performance

An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance.

Financial data

All financial information in this Presentation is in Australian currency (A\$) unless otherwise stated. This Presentation contains historical financial information based on financial information that has been disclosed to the ASX. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding.

Forward-looking statements

This Presentation contains certain 'forward-looking statements', which can generally be identified by the use of forward looking words such as 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance', 'potential' and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements.

Industry and Market data

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

Disclaimer

To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (**Related Persons**) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice.

Two Pivotal Readouts:

A surprising and disappointing outcome

- This has been a very difficult few days for the Company
- Cynata reported top-line results from two pivotal trials
 - the Phase 2 trial of CYP-001 in acute Graft versus Host Disease (aGvHD)
 - and the Phase 3 SCULpTOR trial of CYP-004 in knee osteoarthritis (OA).
- Neither trial met its primary endpoint. There were no statistically significant differences between the active and control groups on the primary or key secondary measures in either study.
- The aGvHD outcome was particularly unexpected. Our Phase 1 trial had delivered strongly positive efficacy signals, giving us firm grounds for confidence that were not reproduced at Phase 2.
- In OA, the active group achieved the pain reduction, but an unusually strong placebo response prevented a treatment effect from being demonstrated.
- Both products were again confirmed to be safe and well tolerated, with adverse event profiles comparable to control.



OA: Phase 3 Results

Key findings:

- There were no safety concerns identified, with a similar adverse event profile between groups.
- There were no statistically significant differences between the active and control groups in either of the co-primary endpoints:
 - The proportion of participants reaching the patient-acceptable symptom state (PASS) threshold for knee pain at 24 months was 51.7% in the active group compared to 48.1% in the control group ($p=0.5907$).
 - There was an average loss of central medial femorotibial (cMFT) cartilage thickness of 0.27mm in the active group compared to 0.21mm in the control group ($p=0.1453$).
- There was a substantial and durable reduction in knee pain intensity at all timepoints from 3-24 months compared to baseline (secondary endpoint), with an average reduction in pain score of 26.8/100 in the active group and 25.3/100 in the control group after 24 months. However, there were no significant differences between groups at any timepoint.
- Analysis of additional outcome measures is ongoing and will be reported in due course



aGvHD: Phase 2 Results

Key Findings:

- There were no safety concerns identified, with a similar adverse event profile between groups.
- There were no significant differences between groups in the primary or key secondary endpoints:

Primary endpoint	Active	Control	P Value ¹
Day 28 Overall Response Rate (ORR)	57.7%	54.8%	>0.9999
Secondary endpoints			
Day 28 Complete Response Rate (CRR)	38.5%	35.5%	>0.9999
Day 100 ORR	23.1%	32.3%	0.5581
Day 100 CRR	19.2%	29.0%	0.5392
Durable ORR (patients with OR at each of Day 28, Day 60 and Day 100)	19.2%	32.3%	0.3681
Day 100 overall survival rate	88.1%	82.3%	0.5137



ersonal use only



Thank You.

Cynata Therapeutics Limited
Level 3, 100 Cubitt Street
Cremorne
VIC 3121
Australia

+61 (03) 7067 6940
investors@cynata.com
www.cynata.com